CLOs on the Move


 
Excerpted from the website: Chimerix discovers, develops and commercializes orally-available, antiviral therapeutics for a broad range of viral diseases, including cytomegalovirus, multi-drug resistant HIV infection and human papilomavirus.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.chimaerix.com
  • 2505 Meridian Pkwy Ste 340
    Durham, NC USA 27713
  • Phone: 919. 806.1074

Executives

Name Title Contact Details

Similar Companies

The START Center for Cancer Care

The START Center offers some of the most sophisticated treatment options available in South Texas along with the world’s largest and most active Phase I clinical trials program. The START Center also offers the Inspiritas Spa and Wellness Center whic...

Viking Therapeutics

Novel therapeutics for metabolic and endocrine disorders

Modern Recovery

[et_pb_section fb_built="1" specialty="on" custom_padding_last_edited="on|tablet" _builder_version="4.6.6" _module_preset="default" background_color="#9e9e9e"

NaturalCheck

NaturalCheck is a Baltimore, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Radionetics

Radionetics Oncology is a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications. The company`s platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes to a broad range of cancers by binding selectively to peptide receptors that are selectively expressed on these tumors. This nonpeptide technology addresses many of the significant challenges currently facing peptide and protein targeted radiotherapeutics, particularly in the realm of optimizing drug-like characteristics and manufacturing. The company is rapidly advancing a pipeline of drug candidates to treat a broad range of cancers and is conducting additional drug discovery efforts to identify drug candidates for additional receptor targets in collaboration with Crinetics Pharmaceuticals.